Through a functional TGF-β signaling pathway and the presence of activating KRAS mutations, TGF-β ligand stimulation promotes tumor cells to undergo epithelial–mesenchymal transition (EMT) and thus develop an aggressive and invasive phenotype (Ellenrieder et al., 2001). This evidence concerns the gene TGFB1 and neoplasm.